Full-Time

Executive Director

Head of Portfolio Management

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$253k - $305kAnnually

Senior, Expert

San Carlos, CA, USA

Hybrid position requiring in-office presence.

Category
Project Management
Strategy Development
Business & Strategy
Required Skills
Data Analysis
Requirements
  • 10+ years' experience in the biotech/pharmaceutical industry with 5+ years' experience in portfolio management, portfolio planning or similar function(s).
  • Experience with clinical development stages and understanding of the external landscape and key players in the Oncology space.
  • Strong insight into strategic and commercial drivers of the pharmaceutical market with a thorough understanding of the drug development and commercialization process.
  • Experience building out (sub)functions and implementing infrastructure and best practice.
  • Exceptional analytical and problem-solving skills, with the ability to interpret complex data, and present it in a clear and concise manner.
  • Proficiency in utilizing data to drive strategic decision making and portfolio optimization.
  • Proven ability to think strategically with sound judgment and decision-making.
  • Demonstrated leadership, influencing skills, critical thinking, creativity, and ability to manage complexity and operate amidst ambiguity.
  • Excellent interpersonal skills and the ability to build and maintain positive work relationships to effectively interface at all levels across the organization.
  • Demonstrated ability to lead cross-functional teams and drive results in a dynamic and fast-paced environment.
  • B.A. or BSc. in Life Sciences with an MSc, MBA or Ph.D. (preferred)
  • Line management experience preferred, matrix management experience acceptable alternative.
Responsibilities
  • Develop and implement a vision for Revolution Medicine’s Portfolio Management function.
  • Lead the build out of the portfolio management capability, partnering with R&D Leadership, Commercial, Finance, Program Management and other functions – including Identify current and future needs and evolve capabilities to remain fit for purpose as our portfolio continues to increase in complexity.
  • Implement best practices including development and use of qualitative and quantitative methods for portfolio prioritization, decision analysis, project trade-offs, and assigning probability of success to support decision making.
  • Develop portfolio dashboards and reports supporting executive decision making.
  • Facilitate and project manage the Portfolio Working Group (PWG) – including Partner with the PWG Chair to define appropriate strategic context for the portfolio and program decisions and execution.
  • Plan and prioritize agenda topics by business criticality ensuring effective and timely discussion and resolution, in partnership with the PWG Chair and Program Team Leads.
  • Prepare stakeholders and presenters and assist in developing appropriate materials.
  • Drive the development and collation of R&D inputs for program and portfolio evaluations, including target product profiles, development plans and probability of success assessment, and ensure consistency with financial and commercial inputs.
  • Closely partner with Program Teams and relevant functions on the application of analytical tools and frameworks to clearly present options and solutions to optimize the portfolio and help them navigate through the relevant decision-making bodies.
  • Maintain a detailed understanding of the shape and drivers of the portfolio through pro-active involvement with key stakeholders and assess impact of external developments on our portfolio.
  • Lead and manage other high impact projects that arise outside of regular portfolio planning cycles, ensuring that these one-off initiatives are aligned to overall business objectives.
  • Contribute to the overall strategy and development of PPAM, as a member of the PPAM LT.
  • Uphold an open, inclusive and collaborative culture with a focus on shared learning and people development.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?